Top Trends Shaping the Biologics and Biosimilars Industry
Executive Summary The Global Biologics and Biosimilars Market is undergoing a transformational expansion driven by the surging prevalence of chronic illnesses, rising demand for cost-effective treatments, and breakthrough advancements in biotechnology. Biologics highly sophisticated molecules such as monoclonal antibodies, recombinant proteins, and vaccines have redefined the treatment paradigms for diseases like cancer, autoimmune disorders, and metabolic syndromes. At the same time, biosimilars are making these cutting-edge therapies more accessible and affordable, especially in emerging economies. According to the latest projections, the global market is expected to rise dramatically from USD 23.96 billion in 2023 to USD 74.85 billion by 2032, registering a robust compound annual growth rate (CAGR) of 17.6%. This remarkable surge reflects not only the clinical efficacy of biologics but also the commercial viability and increasing acceptance of biosimilars across global healthca...